Results 51 to 60 of about 769 (122)
Our current clinical understanding of Candida biofilms: where are we two decades on?
APMIS, Volume 131, Issue 11, Page 636-653, November 2023., 2023 Clinically we have been aware of the concept of Candida biofilms for many decades, though perhaps without the formal designation. Just over 20 years ago the subject emerged on the back of progress made from the bacterial biofilms, and academic progress pace has continued to mirror the bacterial biofilm community, albeit at a decreased volume.
Gordon Ramage +5 more
wiley +1 more source
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
APMIS, Volume 131, Issue 11, Page 654-667, November 2023., 2023 The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID‐19) infection.
Sarah Gaffney +4 more
wiley +1 more source
Internal Medicine Journal, Volume 53, Issue 8, Page 1489-1491, August 2023., 2023 Abstract Scedosporium and Lomentospora species are environmental moulds that are virulent in immunocompromised hosts and rarely cause bloodstream infection (BSI). Patients with Scedosporium and Lomentospora species BSI were identified by the state public laboratory service in Queensland, Australia, over a 20‐year period.
Adam G. Stewart +5 more
wiley +1 more source
A One Health approach to overcoming fungal disease and antifungal resistance
WIREs Mechanisms of Disease, Volume 15, Issue 4, July/August 2023., 2023 A One Health approach to fungal disease integrates environment, animal, and human health to uncover new antifungal therapies and overcome the increasing threat of antifungal resistance. Abstract The global burden of fungal disease poses a substantial threat to human, animal, and environmental health, endangering both human and livestock populations and
Michael Woods +2 more
wiley +1 more source
Antifungal chemotherapies and immunotherapies for the future
Parasite Immunology, Volume 45, Issue 2, February 2023., 2023 Abstract Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response.
Darius Armstrong‐James
wiley +1 more source
A Bibliometric Review on Candida auris of the First Fifteen Years of Research (2009‐2023)
BioMed Research International, Volume 2023, Issue 1, 2023., 2023 Introduction. Candida auris is a relatively novel pathogen first described in 2009 in Japan. It has increased its presence worldwide, becoming a public health concern due to its innate resistance to antifungals and outbreak potential. Methods.
Hiram Villanueva-Lozano +5 more
wiley +1 more source
Journal of Computational Chemistry, Volume 43, Issue 32, Page 2121-2130, December 15, 2022., 2022 The co‐crystal structure of an imidazopyridine ligand (1) complex with Candida albicans Bdf1 BD2, a novel anti‐fungal drug target, reveals that one (W1) among six structural water molecules has been displaced. Molecular dynamic simulations provided insight into the mechanistic role of the displacement process.
Yingsheng Zhou +8 more
wiley +1 more source
APMIS, Volume 130, Issue 9, Page 568-577, September 2022., 2022 Biofilms formed by Candida species present a significant clinical problem due to the ineffectiveness of many conventional antifungal agents, in particular the azole class. We urgently require new and clinically approved antifungal agents quickly for treatment of critically ill patients.
Hafsa Abduljalil +9 more
wiley +1 more source
Cellular Microbiology, Volume 2022, Issue 1, 2022., 2022 Although Candida species are widespread commensals of the microflora of healthy individuals, they are also among the most important human fungal pathogens that under certain conditions can cause diseases (candidiases) of varying severity ranging from mild superficial infections of the mucous membranes to life‐threatening systemic infections.
Dorota Satala +8 more
wiley +1 more source
Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future
Clinical Pharmacology &Therapeutics, Volume 109, Issue 4, Page 867-891, April 2021., 2021 Model‐informed drug development (MIDD) has a long and rich history in infectious diseases. This review describes foundational principles of translational anti‐infective pharmacology, including choice of appropriate measures of exposure and pharmacodynamic (PD) measures, patient subpopulations, and drug‐drug interactions.
Craig R. Rayner +14 more
wiley +1 more source